Hear Dr. Lawrence Eichenfield share the recent consensus definitions from the International Eczema Council.
Dr. Lawrence Eichenfield discusses the meaning of "early intervention" and its potential implications in atopic dermatitis.
Dr. Lawrence Eichenfield shares the cumulative burdens faced by patients with atopic dermatitis.

This cross-TA plenary session addressed challenges in type 2 inflammation-driven diseases. Esteemed faculty, including Profs Klaus Rabe, Sharon Dell, Anju Peters, Milli Gupta, Eric Simpson, Stella Lee, and moderator Oscar Palomares, discussed strategies to enhance quality of life, reduce disease burden, and prioritize patient-centered care.
Drs. Amy Paller and Lisa Swanson discuss the risk of low bone mineral density and impaired growth reported in pediatric atopic dermatitis and observed improvements in growth with advanced therapy, especially among children of shorter stature at baseline.

Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.

Join Dr. Celeste Porsbjerg as she discusses on how IL-13 contributes to mucus plugging in asthma.

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.

In this video from the April 2025 WCPD symposium, Dr Amy Paller discusses the pathophysiology of skin barrier dysfunction in AD and how regulating IL-4 and IL-13 signaling may lead to restoration of the skin barrier. Dr Paller goes on to explore how reducing certain biomarkers, such as CCL17 (TARC), may reduce inflammation that contributes to AD severity in pediatric patients.

Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.